Princeton Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Princeton Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,462	Closed	-$123K	–	99
2020 Q3	$123K	Hold	10,462	–	–	0.05%	93
2020 Q2	$154K	Buy	+10,462	New	+$155K	0.07%	94
2019 Q4	–	Sell	-3,290	Closed	-$63K	–	239
2019 Q3	$63K	Buy	3,290 +1,600	+95%	+$36.7K	0.03%	141
2019 Q2	$50K	Buy	+1,690	New	+$65.1K	0.02%	152

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Princeton Capital Management's AERI Position: Q4 2020 in Review

Princeton Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2020, closing a stake of 10,462 shares — an estimated $123K sold.

Princeton Capital Management first reported a position in AERI in Q2 2019 and held it in 4 quarters. The position peaked at $154K in Q2 2020. 150 funds tracked by Wall St. Rank hold AERI as of Q4 2020.

Princeton Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Princeton Capital Management sold 10,462 Aerie Pharmaceuticals shares in Q4 2020, an estimated $123K.
Princeton Capital Management first reported a position in Aerie Pharmaceuticals in Q2 2019 and held it in 4 quarters.
Princeton Capital Management's Aerie Pharmaceuticals position peaked at $154K in Q2 2020.
150 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2020.

Based on Princeton Capital Management's 13F filing for Q4 2020, filed 11 Feb 2021.